Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

NCT03059563 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT03059563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
Lead sponsor
University of California, Los Angeles
Phase
Phase 1
Overall status
Terminated
Start date
January 11, 2018
Completion date
September 28, 2023
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive function, dopamine d2/3 receptor availability, methamphetamine abuse